5 completed, 4 recruiting, 1 active not recruiting, 1 enrolling by invitation. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 4 | Completed 4 |
Follow Autoimmune Lymphoproliferative Syndrome: new trials by email Literature Review of Autoimmune Lymphoproliferative Syndrome trials Research Report on Autoimmune Lymphoproliferative Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients Soquelitinib - Autoimmune Lymphoproliferative Syndrome | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2025-03-10 | 2026-09-08 |
| Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH) Lymphoproliferative Syndrome, Autoimmune, Lymphoma | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 5500 | 2022-02-01 | 2025-01-17 | |
| Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation Collection of samples - Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 325 | 2021-09-07 | 2026-09-18 | |
| Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC data collection - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Recruiting | Paul Szabolcs | 50 | 2020-08-20 | 2026-01-13 | |
| Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Hydroxyurea, Alemtuzumab, Fludarabine - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Phase 2 | Recruiting | Paul Szabolcs | 100 | 2014-02-04 | 2025-12-15 |
| Immune Disorder HSCT Protocol Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan - Immune Deficiency Disorders, Severe Combined Immunodeficiency | Phase 2 | Active not recruiting | Washington University School of Medicine | 20 | 2013-04-29 | 2026-02-19 |
| Fluorodeoxyglucose Imaging Studies to Detect Lymphoma Autoimmune Lymphoproliferative Syndrome, Lymphoma | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-08-06 | 2019-12-05 | ||
| Comparative Autoantibody and Immunologic Cell Marker Study Autoimmune Diseases, Lupus Erythematosus, Systemic | Enrolling by invitation | Emory University | 2500 | 2012-08-01 | 2026-10-01 | |
| Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Valproic Acid, CT Scan, Blood Sample - ALPS, Hypersplenism | Phase 1 / Phase 2 | Completed | Koneti Rao | 6 | 2008-01-01 | 2013-03-21 |
| Sirolimus for Autoimmune Disease of Blood Cells sirolimus - Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS) | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 30 | 2006-12-01 | 2019-11-19 |
| Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome Pyrimethamine - Autoimmune Disease, Lymphatic Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2003-07-01 | 2008-03-04 |
| Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Fansidar (pyrimethamine and sulfadoxine) - Autoimmune Disease, Lymphoproliferative Disorder | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2001-03-01 | 2008-03-04 |
Autoimmune Diseases (4) · Lymphadenopathy (4) · Lymphohistiocytosis, Hemophagocytic (4) · Arthritis, Juvenile (3) · Arthritis, Rheumatoid (3) · Chediak-Higashi Syndrome (3) · Granulomatous Disease, Chronic (3) · Inflammatory Bowel Diseases (3) · Lupus Erythematosus, Systemic (3) · Lymphoproliferative Disorders (3) · Primary Immunodeficiency Diseases (3) · Purpura, Thrombocytopenic, Idiopathic (3) · Severe Combined Immunodeficiency (3) · Splenomegaly (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Hemic and Lymphatic Diseases (12) · Immunoproliferative Disorders (12) · Immune System Diseases (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (9) · Pathological Conditions, Signs and Symptoms (9) · Autoimmune Diseases (8) · Blood Coagulation Disorders (6) · Hematologic Diseases (6) · Hemorrhagic Disorders (6) · Musculoskeletal Diseases (6) · Pathologic Processes (6) · Connective Tissue Diseases (5)
Melphalan (2) · Pyrimethamine (2) · Thiotepa (2) · fludarabine (2) · Alemtuzumab (1) · Blood Specimen Collection (1) · Data Collection (1) · Hydroxyurea (1) · Sirolimus (1) · Sulfadoxine (1) · Valproic Acid (1) · fanasil, pyrimethamine drug combination (1) · fludarabine phosphate (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Paul Szabolcs (2) · Children's Hospital of Philadelphia (1) · Emory University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Koneti Rao (1) · Washington University School of Medicine (1)
United States (9) · France (1) · Italy (1)
Paul Szabolcs, MD (2) · V. Koneti Rao, M.D. (2) · David T. Teachey, MD (1) · Ignatio Sanz, MD (1) · Koneti Rao, MD (1) · Pier Luigi Zinzani, MD (1)
PMID 19208097, PMID 26504182, PMID 31599480, PMID 32634238, PMID 32750127
R37AI049660 (1)